Eli Income Statement Research

LLY Stock

USD 732.20 13.49 1.81%

Most accounts from Eli Lilly's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Eli Lilly current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Eli Lilly Valuation and Eli Lilly Correlation analysis.

At this time, Eli Lilly's Discontinued Operations is fairly stable compared to the past year. Reconciled Depreciation is likely to rise to about 1.6 B in 2024, whereas Depreciation And Amortization is likely to drop slightly above 994.5 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	21.0B	21.9B	27.5B	28.9B
Total Revenue	28.3B	28.5B	34.1B	35.8B

Gross Profit Total Revenue

Eli Lilly income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Research Development	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Selling And Marketing Expenses	Minority Interest	Tax Provision	Interest Income	Net Interest Income	Discontinued Operations	Reconciled Depreciation
Depreciation And Amortization		0.67	0.58	0.52	0.84	0.32	0.31	0.43	0.92	0.54	0.67	0.08	0.64	0.11	0.66	0.49	0.15	0.08	-0.23	-0.41	0.18	0.09	0.55	-0.37	0.37	-0.2
Interest Expense	0.67		0.75	0.74	0.58	0.69	0.71	0.76	0.59	0.68	0.66	-0.18	0.64	0.09	0.39	0.75	0.41	0.0	-0.46	-0.71	0.33	0.29	0.67	-0.85	0.83	-0.54
Total Revenue	0.58	0.75		1.0	0.71	0.87	0.84	0.89	0.66	0.98	0.62	-0.51	0.54	0.29	0.64	0.98	0.2	-0.12	-0.34	-0.72	0.16	0.31	0.5	-0.62	0.66	0.0
Gross Profit	0.52	0.74	1.0		0.68	0.91	0.86	0.89	0.6	0.98	0.62	-0.52	0.54	0.28	0.62	0.98	0.23	-0.15	-0.32	-0.71	0.17	0.29	0.47	-0.63	0.67	-0.01
Other Operating Expenses	0.84	0.58	0.71	0.68		0.44	0.42	0.5	0.95	0.73	0.72	-0.14	0.61	0.37	0.85	0.63	0.03	0.02	-0.09	-0.37	0.05	0.23	0.34	-0.29	0.31	-0.15
Operating Income	0.32	0.69	0.87	0.91	0.44		0.9	0.9	0.34	0.82	0.62	-0.51	0.6	0.05	0.33	0.9	0.49	-0.28	-0.41	-0.78	0.33	0.11	0.49	-0.73	0.76	-0.01
Ebit	0.31	0.71	0.84	0.86	0.42	0.9		0.99	0.37	0.77	0.4	-0.74	0.34	0.24	0.27	0.86	0.26	0.09	-0.49	-0.75	0.47	0.45	0.55	-0.66	0.69	0.04
Ebitda	0.43	0.76	0.89	0.89	0.5	0.9	0.99		0.47	0.81	0.47	-0.69	0.4	0.23	0.35	0.89	0.27	0.09	-0.5	-0.77	0.47	0.43	0.59	-0.68	0.71	0.02
Cost Of Revenue	0.92	0.59	0.66	0.6	0.95	0.34	0.37	0.47		0.64	0.63	-0.11	0.54	0.32	0.74	0.58	0.02	0.07	-0.26	-0.44	0.05	0.3	0.51	-0.31	0.33	-0.11
Total Operating Expenses	0.54	0.68	0.98	0.98	0.73	0.82	0.77	0.81	0.64		0.58	-0.49	0.49	0.32	0.74	0.95	0.08	-0.11	-0.2	-0.59	0.1	0.27	0.36	-0.51	0.55	0.03
Income Before Tax	0.67	0.66	0.62	0.62	0.72	0.62	0.4	0.47	0.63	0.58		0.22	0.96	0.1	0.57	0.57	0.58	-0.4	-0.15	-0.54	0.03	-0.09	0.51	-0.6	0.58	-0.43
Total Other Income Expense Net	0.08	-0.18	-0.51	-0.52	-0.14	-0.51	-0.74	-0.69	-0.11	-0.49	0.22		0.3	-0.33	-0.07	-0.55	0.24	-0.36	0.3	0.33	-0.36	-0.56	-0.08	0.14	-0.21	-0.45
Net Income	0.64	0.64	0.54	0.54	0.61	0.6	0.34	0.4	0.54	0.49	0.96	0.3		-0.18	0.45	0.5	0.71	-0.51	-0.19	-0.55	0.09	-0.3	0.49	-0.63	0.6	-0.43
Income Tax Expense	0.11	0.09	0.29	0.28	0.37	0.05	0.24	0.23	0.32	0.32	0.1	-0.33	-0.18		0.41	0.23	-0.47	0.43	0.15	0.05	-0.17	0.79	0.05	0.14	-0.09	0.04
Selling General Administrative	0.66	0.39	0.64	0.62	0.85	0.33	0.27	0.35	0.74	0.74	0.57	-0.07	0.45	0.41		0.51	-0.22	0.06	0.32	-0.05	-0.04	0.08	0.02	-0.01	0.02	-0.02
Research Development	0.49	0.75	0.98	0.98	0.63	0.9	0.86	0.89	0.58	0.95	0.57	-0.55	0.5	0.23	0.51		0.26	-0.18	-0.46	-0.79	0.16	0.32	0.52	-0.69	0.74	-0.01
Net Income From Continuing Ops	0.15	0.41	0.2	0.23	0.03	0.49	0.26	0.27	0.02	0.08	0.58	0.24	0.71	-0.47	-0.22	0.26		-0.7	-0.4	-0.62	0.07	-0.36	0.52	-0.71	0.69	-0.38
Non Recurring	0.08	0.0	-0.12	-0.15	0.02	-0.28	0.09	0.09	0.07	-0.11	-0.4	-0.36	-0.51	0.43	0.06	-0.18	-0.7		0.1	0.33	0.51	0.53	-0.09	0.37	-0.38	0.15
Non Operating Income Net Other	-0.23	-0.46	-0.34	-0.32	-0.09	-0.41	-0.49	-0.5	-0.26	-0.2	-0.15	0.3	-0.19	0.15	0.32	-0.46	-0.4	0.1		0.82	-0.25	-0.35	-0.78	0.65	-0.67	0.07
Selling And Marketing Expenses	-0.41	-0.71	-0.72	-0.71	-0.37	-0.78	-0.75	-0.77	-0.44	-0.59	-0.54	0.33	-0.55	0.05	-0.05	-0.79	-0.62	0.33	0.82		-0.2	-0.27	-0.85	0.87	-0.9	0.15
Minority Interest	0.18	0.33	0.16	0.17	0.05	0.33	0.47	0.47	0.05	0.1	0.03	-0.36	0.09	-0.17	-0.04	0.16	0.07	0.51	-0.25	-0.2		0.04	0.29	-0.14	0.1	0.14
Tax Provision	0.09	0.29	0.31	0.29	0.23	0.11	0.45	0.43	0.3	0.27	-0.09	-0.56	-0.3	0.79	0.08	0.32	-0.36	0.53	-0.35	-0.27	0.04		0.33	-0.16	0.2	-0.05
Interest Income	0.55	0.67	0.5	0.47	0.34	0.49	0.55	0.59	0.51	0.36	0.51	-0.08	0.49	0.05	0.02	0.52	0.52	-0.09	-0.78	-0.85	0.29	0.33		-0.71	0.7	-0.19
Net Interest Income	-0.37	-0.85	-0.62	-0.63	-0.29	-0.73	-0.66	-0.68	-0.31	-0.51	-0.6	0.14	-0.63	0.14	-0.01	-0.69	-0.71	0.37	0.65	0.87	-0.14	-0.16	-0.71		-0.99	0.53
Discontinued Operations	0.37	0.83	0.66	0.67	0.31	0.76	0.69	0.71	0.33	0.55	0.58	-0.21	0.6	-0.09	0.02	0.74	0.69	-0.38	-0.67	-0.9	0.1	0.2	0.7	-0.99		-0.46
Reconciled Depreciation	-0.2	-0.54	0.0	-0.01	-0.15	-0.01	0.04	0.02	-0.11	0.03	-0.43	-0.45	-0.43	0.04	-0.02	-0.01	-0.38	0.15	0.07	0.15	0.14	-0.05	-0.19	0.53	-0.46

Click cells to compare fundamentals

Eli Lilly Account Relationship Matchups

Eli Lilly income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	400.6M	359.6M	339.8M	331.6M	312.3M	327.9M
Total Revenue	22.3B	24.5B	28.3B	28.5B	34.1B	35.8B
Gross Profit	17.6B	19.1B	21.0B	21.9B	27.5B	28.9B
Operating Income	5.0B	6.1B	6.4B	7.1B	10.3B	10.8B
Ebit	5.0B	6.1B	6.4B	7.1B	10.9B	11.5B
Ebitda	6.6B	7.6B	8.7B	9.4B	12.5B	13.1B
Cost Of Revenue	4.7B	5.5B	7.3B	6.6B	6.6B	3.6B
Income Before Tax	5.3B	7.2B	6.2B	6.8B	6.6B	3.5B
Net Income	4.6B	6.2B	5.6B	6.2B	5.2B	2.7B
Income Tax Expense	628M	1.0B	573.8M	561.6M	1.3B	810.6M
Research Development	5.6B	6.1B	7.0B	7.2B	9.3B	9.8B
Non Recurring	2.8B	2.5B	815.2M	244.6M	281.3M	267.2M
Minority Interest	75.7M	1.1B	92.2M	183.6M	211.1M	241.8M
Tax Provision	628M	1.0B	573.8M	561.6M	1.3B	989.6M
Interest Income	80.4M	326.6M	314.4M	268.8M	173.6M	204.8M
Net Interest Income	(320.2M)	(326.6M)	(314.4M)	(268.8M)	(312.3M)	(327.9M)

Eli Lilly Investors Sentiment

The influence of Eli Lilly's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Eli. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Eli Lilly's public news can be used to forecast risks associated with an investment in Eli. The trend in average sentiment can be used to explain how an investor holding Eli can time the market purely based on public headlines and social activities around Eli Lilly and. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Eli Lilly's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Eli Lilly's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Eli Lilly's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Eli Lilly.

Eli Lilly Implied Volatility

42.0

Eli Lilly's implied volatility exposes the market's sentiment of Eli Lilly and stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Eli Lilly's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Eli Lilly stock will not fluctuate a lot when Eli Lilly's options are near their expiration.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eli Lilly in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eli Lilly's short interest history, or implied volatility extrapolated from Eli Lilly options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:

How To Invest In Eli

Details

Is Eli Stock a good investment?

Details

What is Eli Lilly's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Eli Lilly Valuation and Eli Lilly Correlation analysis.

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.

	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	CEOs Directory Screen CEOs from public companies around the world
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Commodity Directory Find actively traded commodities issued by global exchanges
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges

Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.13

Dividend Share

4.52

Earnings Share

5.82

Revenue Per Share

37.908

Quarterly Revenue Growth

0.281

The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eli Income Statement Research

Eli Lilly income statement Correlations

Eli Lilly Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eli Lilly income statement Accounts

Eli Lilly Investors Sentiment

Eli Lilly Implied Volatility

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Eli Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Ebitda	+ 0.99	Ebit
Total Operating Expenses	+ 0.98	Total Revenue
Research Development	+ 0.98	Total Revenue
Total Operating Expenses	+ 0.98	Gross Profit
Research Development	+ 0.98	Gross Profit

Discontinued Operations	- 0.99	Net Interest Income
Discontinued Operations	- 0.9	Selling And Marketing Expenses
Interest Income	- 0.85	Selling And Marketing Expenses
Net Interest Income	- 0.85	Interest Expense
Selling And Marketing Expenses	- 0.79	Research Development
Interest Income	- 0.78	Non Operating Income Net Other